Overview
Simbec-Orion is a global full-service contract research organization (CRO) that designs and manages clinical trials from First-in-Human studies through Phase III and post-marketing research. Its service offering includes an end-to-end suite of clinical development activities and integrated support services, with deep expertise in clinical pharmacology, oncology, and rare diseases. The company tailors, scales, and adapts its delivery, communications, and operations to fit the needs of small- and mid-size drug developers, aiming to accelerate the availability of improved medicines for patients. Unlike generic CROs, Simbec-Orion emphasizes flexibility, bespoke and scalable solutions, and a partnership approach to align project execution with clients’ clinical and commercial goals.
Work here?Claim your company
Simplify's take
What believers are saying
- March 18, 2026 Cambridge office expands Boston access to biotech decision-makers.
- June 30, 2026 combination broadens U.S., Europe, APAC, and China commercial reach.
- AI partnership with biotx.ai and Avance Clinical partnership deepen differentiated trial-design capabilities.
What critics are saying
- Integration under Caidya's brand can distract teams and trigger sponsor churn through 2027.
- CBPE ownership and a 2026 combination increase pressure for cost cuts and cross-selling.
- If major biotech clients defect, Simbec-Orion loses the specialist edge that justified the deal.
What makes Simbec-Orion unique
- June 2026 Caidya combination links Simbec-Orion Phase I expertise to global execution.
- Its 48-bed Phase I unit gives sponsors fast first-in-human to registration continuity.
- Fifty years in oncology and rare disease builds credibility with specialist biotech buyers.
Help us improve and share your feedback! Did you find this helpful?